Association of dose escalation of octreotide long‐acting release on clinical symptoms and tumor markers and response among patients with neuroendocrine tumors

By  

Cancer Medicine, Vol. 4, Iss. 6, 2015-06 ,pp. : 864-870

John Wiley & Sons Inc

Access to resources Recommend Favorite

Resolution of refractory chemotherapy-induced diarrhea (CID) with octreotide long-acting formulation in cancer patients: 11 case studies

By Rosenoff Stephen  

Supportive Care in Cancer, Vol. 12, Iss. 8, 2004-08 ,pp. : 561-570

Springer Publishing Company

Access to resources Recommend Favorite

The value of radiolabelled MIBG and octreotide in the diagnosis and management of neuroendocrine tumours

By Kaltsas G.   Mukherjee J.   Grossman A.  

Annals of Oncology, Vol. 12, Iss. 2, 2001-02 ,pp. : 47-50

Springer Publishing Company

Access to resources Recommend Favorite

Treatment with High Dose [¹¹¹In-DTPA-D-PHE¹]-Octreotide in Patients with Neuroendocrine Tumors: Evaluation of Therapeutic and Toxic Effects

By Janson Eva Tiensuu   Eriksson Barbro   Öberg Kjell   Skogseid Britt   Öhrvall Ulf   Nilsson Sten   Westlin Jan-Erik  

Acta Oncologica, Vol. 38, Iss. 3, 1999-05 ,pp. : 373-377

Informa Healthcare

Access to resources Recommend Favorite

Octreotide in the Management of Bowel Obstruction in Terminal Ovarian Cancer

By Mangili G.   Franchi M.   Mariani A.   Zanaboni F.   Rabaiotti E.   Frigerio L.   Bolis P.F.   Ferrari A.  

Gynecologic Oncology, Vol. 61, Iss. 3, 1996-06 ,pp. : 345-348

Academic Press

Access to resources Recommend Favorite